Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma Exchange with Albutein 5% in ALS
NCT02872142Phase 2Completed
- Sponsor
- Grifols
- Start
- Aug 2016
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human albumin in amyotrophic lateral sclerosis (ALS), sponsored by Grifols. Primary endpoints: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 48 weeks and Forced Vital Capacity at 48 weeks. Started Aug 2016; status: completed.
02
Drugs
human albumin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02872142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02872142.